Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isotretinoin - Nova Laboratories

Next Previous
Drug Profile

Isotretinoin - Nova Laboratories

Alternative Names: 13 cis retinoic acid; 13-CRA

Latest Information Update: 25 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nova Biopharma
  • Developer Nova Laboratories
  • Class Anti-inflammatories; Antiacnes; Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuroblastoma

Most Recent Events

  • 17 Mar 2021 Isotretinoin is still in phase I/II trials for Neuroblastoma (In infants, In neonates, In children, In adults, In adolescents) in United Kingdom (PO)
  • 04 Jan 2019 Chemical structure information added
  • 17 Apr 2018 Phase-I/II clinical trials in Neuroblastoma (In infants, In neonates, In children, In adults, In adolescents) in United Kingdom (PO) (NCT03291080) (EudraCT2016-005104-25)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top